BPC-157 vs Chonluten
Extensively Studied vs Moderate Research
compatible Both support mucosal health through different mechanisms.
Molecular Data
BPC-157 Chonluten
Weight 1,419.53 Da 319 Da
Half-life <30 minutes Minutes (short peptide); effects persist via epigenetic changes
Chain 15 amino acids 3 amino acids
Type Pentadecapeptide Tripeptide bioregulator
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Chonluten
01 Normalizes respiratory system function
02 Regulates protein synthesis in lung tissue
03 Inhibits inflammatory TNF production
04 Restores lung alveolar tissues
05 Maintains bronchial mucous membranes
06 Supports antioxidant gene expression
07 May slow cell aging (geroprotective)
08 Modulates mucosal function
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Chonluten
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Chonluten
Generally well-tolerated
Minimal side effects reported
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
BPC-157 Chonluten
Status Extensively Studied Moderate Research
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.